Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

More than 30 days of previous treatment (before screening) with anti-myeloma therapy (does not include radiotherapy or a single short course of steroid [ie, less than or equal to the equivalent of dexamethasone 60 mg/day for 4 days]).

Planned radiation therapy or surgery to the bone (does not include procedures performed before randomization)

Prior administration of denosumab

Use of oral bisphosphonates with a cumulative exposure of more than 1 year

More than 1 previous dose of IV bisphosphonate administration

Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw

Evidence of any of the following conditions per subject self-report or medical chart review: Any prior invasive malignancy within 5 years before randomization/ Any non-invasive malignancy not treated with curative intent or with knownactive disease within 5 years before randomization/ Major surgery or significant traumatic injury occurring within 4 weeks before randomization/ Active infection with Hepatitis B virus or Hepatitis C virus/ Known infection with human immunodeficiency virus (HIV)/ Active infection requiring IV anti-infective therapy

Subject is pregnant or breast feeding, or planning to become pregnant within 5 months after end of treatment

Female subject of child bearing potential is not willing to use highly effective contraception during treatment and for 5 months after the end of treatment (see section 6.3)

Known sensitivity to any of the products to be administered during the study (eg, mammalian derived products, calcium or vitamin D)

Subject is receiving or is less than 30 days since ending other experimental device or drug (no marketing authorization for any indication)

Subject will not be available for follow-up assessment

Any major medical or psychiatric disorder that in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results